Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Overall investment in the US facility is estimated around US$50 million
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
